Mitchell Lawrence Jones, serving as the Chief Medical Officer for Palisade Bio, Inc. (NASDAQ: PALI), executed a sale of company equity on July 7, 2026. The transaction involved the disposition of 51,880 shares of common stock, generating a total proceeds value of $106,535. The execution of this sale occurred within a specific price band, with a weighted average transaction price of $2.0535 per share. Individual trades within this block were recorded between $2.045 and $2.06 per share.
The primary catalyst for this divestiture was the settlement of tax withholding obligations. The sale was directly linked to the vesting and settlement of Restricted Stock Units (RSUs) that had been granted to Mr. Jones on February 9, 2026. Prior to the execution of the sale, on July 6, 2026, Mr. Jones acquired 131,167 shares of common stock at no cost. These shares were delivered through the settlement of vested RSUs. Each of these units represented a contingent right to receive one share of Palisade Bio common stock upon meeting specific conditions.
Following the completion of these transactions, Mr. Jones maintains a direct ownership position of 94,009 shares of Palisade Bio common stock. This holding includes 1,459 shares that were acquired under the company’s Employee Stock Purchase Plan on May 20, 2026. Furthermore, Mr. Jones retains a significant portfolio of 655,833 Restricted Stock Units. These units are scheduled to vest in installments, with a portion vesting on July 6, 2026, and quarterly thereafter over the subsequent 10 quarters. The vesting schedule is contingent upon his continuous service to the company.
Market data indicates that Palisade Bio stock currently trades at $2.04, which is near its 52-week high of $2.85. The stock has experienced a substantial 184% return over the past year. Analyst notes suggest that the stock price movements are quite volatile, which may explain the timing of the executive’s tax-related sale. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value. Investors can access 12 additional ProTips and comprehensive financial metrics on the platform.
In parallel with the insider activity, Palisade Bio has advanced its clinical pipeline. The company received clearance from the U.S. Food and Drug Administration for its Investigational New Drug application for PALI-2108. This regulatory approval permits the company to initiate a Phase 2 clinical trial, designated as ASCENTRA-UC. The trial targets patients with moderately to severely active ulcerative colitis. The study is expected to enroll up to 204 patients across North America and Europe. Enrollment is scheduled to begin in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.
Market analysts have responded to these developments. H.C. Wainwright reiterated its Buy rating on Palisade Bio, maintaining a price target of $7.00 following the FDA’s clearance for the trial. Additionally, Palisade Bio presented new pharmacokinetic data for PALI-2108, indicating promising results in its Phase 1a/b analyses. The data showed that the active metabolite exceeded key concentration thresholds, with significant tissue-to-plasma exposure ratios.
Palisade Bio also announced corporate governance changes. The company appointed Robert Baltera and Jordan Zwick to its Board of Directors, bringing extensive biotech expertise to the leadership team. Baltera’s background includes senior roles at Amgen and leadership at Amira Pharmaceuticals, which was sold to Bristol-Myers Squibb. These developments highlight Palisade Bio’s ongoing efforts in advancing its ulcerative colitis treatment and strengthening its leadership team.